PDF   Print   View All
March 13, 2003
Call to focus on Recent Acquisition, Funding and Forward Commercialization Strategies

Philadelphia, PA, Thursday, March 13, 2003: Hemispherx Biopharma Inc. (AMEX: HEB), a leading company in the experimental-stage development of immune based therapies primarily addressing the diseases of HIV/AIDS and Chronic Fatigue Syndrome, announced today that it will be hosting a conference call on Tuesday, March 18, 2003 at 11:00AM Eastern Standard Time (EST).

In order to participate in this conference call, please call:

U.S. and Canada: (800) 915 - 4836
International: 1 973 317 5319
Leader: Wesley Stanton
Pass Code: Hemispherx

The conference call will focus on the company’s recent acquisition of certain assets from Interferon Sciences, Inc., the recent $5,500,000 financing the Company completed and the forward strategies for the commercialization of the Company’s pharmaceutical pipeline. Additionally, there will be a 15-minute period at the end of the call for questions.

It is suggested you please place your call no later then 10:50am EST on Tuesday morning. Due to the overwhelming response to our last conference call, please submit all questions prior to the call and they will be addressed during the last 15 minutes of the presentation. To submit a question, please email wstanton@mrb-ir.com or fax them to (212) 495 – 0746, Attention: Wesley Stanton, Regarding: Hemispherx Conference Call.

About Hemispherx

Hemispherx Biopharma, based in Philadelphia, is a biopharmaceutical company engaged in the manufacture and global clinical development of new drug entities in the nucleic acid (NA) class for chronic viral diseases and disorders of the Immune system including, HIV, CFS and Hepatitis. Its platform technology includes large and small agent components for potential treatment of various chronic viral infections. For more information visit the company’s Web site at www.Hemispherx.net.

Hemispherx Biopharma, Inc., Investor Relations
Dianne Will, Investor Relations
(518) 398-6222, Fax: (518) 398-6223

Wesley Stanton, MRB Investor Relations
(212) 495-0200, Fax: (212) 495-0746

HEB's Web Site: www.hemispherx.net

Information contained in this news release other than historical information, should be considered forward-looking and is subject to various risk factors and uncertainties. For instance, the strategies and operations of Hemispherx involve risk of competition, changing market conditions, change in laws and regulations affecting these industries and numerous other factors discussed in this release and in the Company's filings with the Securities and Exchange Commission. Accordingly, all the referenced investigational drugs and associated technologies of the company are experimental in nature and as such are not designated safe and effective by a regulatory authority for general use and are legally available only through clinical trials with the referenced disorders. The forward-looking statements represent the Company's judgment as of the date of this release. The Company disclaims, however, any intent or obligation to update these forward-looking statements.